| scholarly article | Q13442814 |
| P50 | author | Csaba P. Kovesdy | Q5191546 |
| Fridtjof Thomas | Q40293652 | ||
| P2093 | author name string | Nabil Jarmukli | |
| Geeta Gyamlani | |||
| Jun Ling Lu | |||
| Zhongji Han | |||
| L. Darryl Quarles | |||
| Adnan Naseer | |||
| Angela Wallick | |||
| Barry M. Wall | |||
| P2860 | cites work | Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials | Q40523566 |
| Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. | Q40575947 | ||
| Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. | Q43114586 | ||
| High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients | Q44977753 | ||
| FGF-23 is elevated by chronic hyperphosphatemia | Q45050609 | ||
| Serum phosphate levels and mortality risk among people with chronic kidney disease | Q45198981 | ||
| Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients | Q46122319 | ||
| Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
| Effect of phosphorus restriction on renal response to oral and intravenous protein loads in rats. | Q51601111 | ||
| Regulation of intestinal phosphate transport. I. Segmental expression and adaptation to low-P(i) diet of the type IIb Na(+)-P(i) cotransporter in mouse small intestine. | Q54681432 | ||
| The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer | Q57221098 | ||
| Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial | Q58946610 | ||
| Phosphate regulation of vascular smooth muscle cell calcification | Q28139908 | ||
| Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD | Q30429870 | ||
| Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial | Q33937415 | ||
| Control of phosphate excretion in uremic man | Q34277981 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| Phosphorus binders and survival on hemodialysis | Q34907022 | ||
| BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells | Q35643930 | ||
| Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. | Q36104887 | ||
| Effects of phosphate binders in moderate CKD | Q36109201 | ||
| The assessment of endothelial function: from research into clinical practice | Q36190146 | ||
| Npt2b deletion attenuates hyperphosphatemia associated with CKD. | Q36280326 | ||
| FGF23: its role in renal bone disease | Q36577606 | ||
| Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial | Q37042040 | ||
| Bone and mineral disorders in pre-dialysis CKD. | Q37119865 | ||
| Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. | Q37416887 | ||
| On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". | Q39914380 | ||
| Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes | Q40226740 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nephrology | Q177635 |
| P304 | page(s) | 897-904 | |
| P577 | publication date | 2018-03-23 | |
| P1433 | published in | KI reports | Q27727507 |
| P1476 | title | Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial. | |
| P478 | volume | 3 |
| Q64117955 | Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study | cites work | P2860 |
Search more.